Mesa Laboratories, Inc. Form 10-Q Summary
Reporting period: The filing covers the three months ended June 30, 2013, and was filed August 7, 2013. The request metadata identifies “2012 Q1,” but the filing text clearly reports the June 30, 2013 quarter. Mesa develops and sells quality-control products through its Biological Indicators and Instruments divisions.
Financial Performance and Position
| Metric | Q1 FY2014 | Q1 FY2013 | Change |
|---|---|---|---|
| Revenue | $11.218 million | $10.559 million | +6% |
| Gross profit | $6.797 million | $6.455 million | +5% |
| Gross margin | 61% | 61% | Flat |
| Operating income | $3.043 million | $3.219 million | Decrease |
| Net income | $1.860 million | $2.099 million | -11% |
| Diluted EPS | $0.52 | $0.59 | Decrease |
| Net profit margin | 17% | 20% | Down 3 percentage points |
- Biological Indicators revenue declined 5% to $4.854 million, while Instruments revenue increased 17% to $6.364 million.
- Biological Indicators gross margin declined to 53% from 57%, primarily because of replacement product costs and lower volume. Instruments gross margin improved to 67% from 65%.
- Operating expenses increased 16% to $3.754 million, including increases of 8% in selling expense, 13% in general and administrative expense, and 54% in research and development expense.
- The effective tax rate increased to 38.3% from 34.1%; management expects the rate to approximate 38.3% going forward.
- Operating cash flow was $2.805 million, compared with $3.412 million in the prior-year quarter. Capital expenditures were $415,000.
- Cash declined to $3.589 million from $4.006 million at March 31, 2013. Working capital was $14.403 million, compared with $14.793 million at March 31, 2013.
- Long-term debt declined to $1.500 million from $4.000 million after a $2.500 million repayment during the quarter. The company had $18.500 million of unused revolving credit capacity at June 30, 2013.
- The company paid $474,000 in dividends and received $182,000 from stock-option exercises. No acquisition cash outlay occurred during the quarter.
Material Changes Versus the Prior Comparable Period
- Revenue growth was driven by the Bios acquisition, which contributed to a full quarter of Instruments results in 2013; legacy Instruments product lines were described as relatively unchanged.
- Biological Indicators revenue and gross profit were adversely affected by three product batches with longer-than-expected incubation times. Mesa replaced the batches, reducing product available for new orders and increasing the quarter-end backlog.
- Management implemented spore-crop screening procedures intended to identify similar issues before manufacture or shipment.
- Higher operating expenses reflected a full quarter of Bios-related costs, additional personnel, salary adjustments, and increased research and development consulting costs.
- Net income declined despite higher revenue and gross profit because operating expenses and the effective tax rate increased.
- The prior-year quarter included the $16.660 million Bios acquisition, $11.000 million of related debt borrowings, and materially higher investing and financing cash flows.
Guidance, Outlook, Risks, and Unusual Items
- Management expects biological indicator markets to remain strong and intends to pursue organic growth, new products, and additional acquisitions.
- Instrument demand remains strong, but management noted that the discretionary nature of instrument purchases makes the business more exposed to weak global economic conditions, tighter credit, and delayed customer capital spending.
- Management expects Sarbanes-Oxley compliance costs to remain relatively flat and may continue investing in personnel and information systems.
- The Bios acquisition includes contingent consideration based on revenue growth. The potential undiscounted payment ranges from zero to $6.710 million; the recorded liability was $2.152 million at June 30, 2013. Payment is expected in the first quarter of fiscal 2016, and management reported no material change during the quarter.
- Mesa recorded a $100,000 estimated state sales-tax liability. Potential exposure in additional states remained unquantified.
- Open purchase orders totaled $1.308 million, payable within one year. Additional payments of up to $225,000 may be due under a biological-indicator technology license if development and performance milestones are met.
- On July 1, 2013, Mesa acquired the SureTorque bottle-cap torque-testing business for $1.821 million, comprising $1.721 million paid at closing and a $100,000 holdback expected to be settled July 1, 2014.
- In July 2013, Mesa made an additional $1.000 million debt repayment. In August 2013, the board declared a $0.14-per-share quarterly dividend payable September 18, 2013.
- The company reported no material changes to previously disclosed risk factors, no derivative instruments, and minimal foreign-currency and commodity exposure. A one-percentage-point increase in interest rates would have increased quarterly interest expense by approximately $33,000 based on average variable-rate debt.
- Management concluded that disclosure controls and internal control over financial reporting were effective as of June 30, 2013, with no significant control changes during the quarter.
Important Facts for Investors to Verify
- Confirm the applicable reporting period: the filing reports June 30, 2013, despite the request metadata referencing 2012 Q1.
- Assess whether the Biological Indicators batch-replacement issue and related backlog were resolved without further margin or revenue effects.
- Evaluate the sustainability of Instruments revenue growth following the Bios acquisition and the performance of legacy product lines.
- Monitor contingent consideration exposure of up to $6.710 million and the unresolved potential state sales-tax liability.
- Verify post-quarter-end effects of the SureTorque acquisition, the additional debt repayment, and the declared dividend.
- Review covenant compliance and remaining availability under the variable-rate credit facility, which matures in February 2015.